Download PDF
Thromb Haemost 1999; 82(03): 1188-1195
DOI: 10.1055/s-0037-1614351
Letters to the Editor
Schattauer GmbH

A Human Antibody that Binds to the γ-carboxyglutamic Acid Domain of Factor IX Is a Potent Antithrombotic In Vivo

Canio J. Refino
1   From the Genentech Inc., Cardiovascular Research and Antibody Technologies Departments, South San Francisco, CA, USA
,
Jacques Himber
2   F. Hoffmann-La Roche, Preclinical Research, Basel, Switzerland
,
Louis Burcklen
2   F. Hoffmann-La Roche, Preclinical Research, Basel, Switzerland
,
Paul Moran
1   From the Genentech Inc., Cardiovascular Research and Antibody Technologies Departments, South San Francisco, CA, USA
,
Mark Peek
1   From the Genentech Inc., Cardiovascular Research and Antibody Technologies Departments, South San Francisco, CA, USA
,
Shelley Suggett
1   From the Genentech Inc., Cardiovascular Research and Antibody Technologies Departments, South San Francisco, CA, USA
,
Brigitte Devaux
1   From the Genentech Inc., Cardiovascular Research and Antibody Technologies Departments, South San Francisco, CA, USA
,
Daniel Kirchhofer
1   From the Genentech Inc., Cardiovascular Research and Antibody Technologies Departments, South San Francisco, CA, USA
› Author Affiliations
Further Information

Publication History

Received 12 March 1999

Accepted after revision 14 May 1999

Publication Date:
09 December 2017 (online)

    Permissions and Reprints

Summary

10C12, a human antibody F(ab’)2, which specifically binds to the Gla domain of factor IX, interfered with all known coagulation processes that involve factor IX/IXa. These include the function of the intrinsic Xase complex and the activation of zymogen factor IX by factor XIa and by the tissue factor:factor VIIa complex. Furthermore, 10C12 potently inhibited activated partial thromboplastin clotting times (APTT) in plasma of guinea pig and rat, thus enabling in-vivo evaluation. In guinea pigs, a bolus administration of 10C12 (10 μg/kg) prevented cyclic flow variations in damaged carotid arteries without affecting coagulation or bleeding parameters. At a 100-fold higher dose, 10C12 had no effect on normal hemostasis as assessed by the cuticle bleeding time. At this dose, 10C12 was also efficacious in a rat arterial thrombosis model, substantially reducing clot weight and duration of vessel occlusion while prolonging ex-vivo APTT only 1.2-fold. The dose of heparin required to produce comparable antithrombotic effects prolonged the APTT by 12-fold and increased the tail bleeding time (TBT) by 8-fold. In contrast, 10C12 had no effect on TBT. However, rat tails showed a tendency for rebleeding which 10C12 exacerbated. In conclusion, the antithrombotic potency of the 10C12 antibody in two species provides evidence for an important role of F.IX, and its Gla domain in particular, during thrombogenesis under arterial flow conditions. The relative safety at effective doses of this fully human antibody suggests that it may have therapeutic value for treatment of thrombotic disorders.

Abbreviations

Gla: γ-carboxyglutamic acid; CDRs: complementarity determining regions; CVFs: cyclic flow variations; TF:F.VIIa: tissue factor:factor VIIa; APTT: activated partial thromboplastin time; PT: prothrombin time; ACT: whole blood activated clotting time; CBT: cuticle bleeding time; TBT: tail bleeding time

 

  • References

  • 1 Harker LA, Hanson SR, Wilcox JN, Kelly AB. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway. Haemostasis 1996; 26: 76-82.
    PubMedGoogle Scholar
  • 2 Benedict CR, Ryan J, Wolitzky B, Ramos R, Gerlach M, Tijburg P, Stern D. Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. J Clin Invest 1991; 88: 1760-65.
    CrossrefPubMedGoogle Scholar
  • 3 Spanier TB, Oz MC, Minanov OP, Simantov R, Kisiel W, Stern DM, Rose EA, Schmidt AM. Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog. J Thoracic Cardiovasc Surgery 1998; 115: 1179-88.
    PubMedGoogle Scholar
  • 4 Fujikawa K, Legaz ME, Kato H, Davie EW. The mechanism of activation of bovine factor IX (Christmas factor) by bovine factor XIa (activated plasma thromboplastin antecedent). Biochemistry 1974; 13: 4508-16.
    CrossrefPubMedGoogle Scholar
  • 5 Østerud B, Bouma BN, Griffin JH. Human blood coagulation factor IX. Purification, properties, and mechanism of activation by activated factor XI. J Biol Chem 1978; 253: 5946-51.
    PubMedGoogle Scholar
  • 6 Østerud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and Factor VII: Additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-4.
    CrossrefPubMedGoogle Scholar
  • 7 Ahmad SS, Walsh PN. Platelet membrane-mediated coagulation protease complex assembly. Trends Cardiovasc Med 1994; 4: 271-7.
    CrossrefPubMedGoogle Scholar
  • 8 Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. Sem Hematol 1992; 29: 213-26.
    PubMedGoogle Scholar
  • 9 Toomey JR, Smith KJ, Roberts HR, stafford DW. The endothelial cell binding determinant of human factor IX resides in the γ-carboxyglutamic acid domain. Biochemistry 1992; 31: 1806-8.
    CrossrefPubMedGoogle Scholar
  • 10 Cheung W-F, Hamaguchi N, Smith KJ, Stafford DW. The binding of human factor IX to endothelial cells is mediated by residues 3-11. J Biol Chem 1992; 267: 20529-31.
    CrossrefPubMedGoogle Scholar
  • 11 Rawala-Sheikh R, Ahmad SS, Monroe DM, Roberts HR, Walsh PN. Role of γ-carboxyglutamic acid residues in the binding of factor IXa to platelets and in factor-X activation. Blood 1992; 79: 398-405.
    PubMedGoogle Scholar
  • 12 Cheung W-F, Van den Born J, Kuhn K, Kjellen L, Hudson BG, Stafford DW. Identification of the endothelial cell binding site for factor IX. Proc Natl Acad Sci USA 1996; 93: 11068-73.
    CrossrefPubMedGoogle Scholar
  • 13 Sugo T, Mizuguchi J, Kamikubo Y, Matsuda M. Anti-human factor IX monoclonal antibodies specific for calcium ion-induced conformations. Thromb Res 1990; 58: 603-14.
    CrossrefPubMedGoogle Scholar
  • 14 Liebman HA, Furie BC, Furie B. The factor IX phospholipid-binding site is required for calcium-dependent activation of factor IX by factor XIa. J Biol Chem 1987; 262: 7605-12.
    PubMedGoogle Scholar
  • 15 Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-44.
    CrossrefPubMedGoogle Scholar
  • 16 Sherman-Gold R. Monoclonal antibodies: the evolution from ’80s magic bullets to mature, mainstream applications as clinical therapeutics. Genetic engineering news 1997; 17.
    PubMedGoogle Scholar
  • 17 Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, Johnson KS. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nature Biotechnology 1996; 14: 309-14.
    CrossrefPubMedGoogle Scholar
  • 18 Suggett S, Refino C, Hass P, Nagel M, Lipari T, Moran K, Judice K, Schroeder H, Lowman C, Adams C, Eaton D, Devaux B, Kirchhofer D. Use of phage display for the generation of human antibodies that neutralize Factor IX function. Blood 1998; 92: 55 (Abstr).
    PubMedGoogle Scholar
  • 19 Kelley RF, Refino CJ, O’Connell MP, Modi N, Sehl P, Lowe D, Pater C, Bunting S. A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent. Blood 1997; 89: 3219-27.
    PubMedGoogle Scholar
  • 20 Carter P, Kelley RF, Rodrigues ML, Snedecor B, Covarrubias M, Velligan MD, Wong WLT, Rowland AM, Kotts CE, Carver ME, Yang M, Bourell JH, Shepard HM, Henner D. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Bio/Technology 1992; 10: 163-7.
    CrossrefPubMedGoogle Scholar
  • 21 Kostelny SA, Cole MS, Tso JY. Formation of a bispecific antibody by the use of leucine zippers. J Immunol 1992; 148: 1547-53.
    PubMedGoogle Scholar
  • 22 Carteaux JP, Gast A, Tschopp TB, Roux S. Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis. Circulation 1995; 91: 1568-74.
    CrossrefPubMedGoogle Scholar
  • 23 Himber J, Kirchhofer D, Riederer M, Tschopp TB, Steiner B, Roux SP. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function. Thromb Haemost 1997; 78: 1142-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990; 60: 269-80.
    CrossrefPubMedGoogle Scholar
  • 25 Dejana E, Villa S, de Gaetano G. Bleeding time in rats: a comparison of different experimental conditions. Thromb Haemost 1982; 48: 108-11.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Sturzebecher J, Kopetzki E, Bode W, Hopfner K-P. Dramatic enhancement of the catalytic activity of coagulation factor IXa by alcohols. FEBS letters 1997; 412: 295-300.
    CrossrefPubMedGoogle Scholar
  • 27 Neuenschwander PF, McCollough J, McCallum CD, Johnson AE. A conformational change in the active site of blood coagulation factor IXa is associated with an increase in activity upon treatment with ethylene glycol. Thromb Haemost 1997; 78 (suppl.) 428 (abstr.)
    PubMedGoogle Scholar
  • 28 Giles AR, Tinlin S, Greenwood R. A canine model of hemophilic (Factor VIII:C deficiency) bleeding. Blood 1982; 60: 727-30.
    PubMedGoogle Scholar
  • 29 Stenflo J, Dahlbäck B. Vitamin-K dependent proteins. In: The molecular basis of blood diseases. 2nd ed.. Philadelphia: W. B. Saunders, Company; 1994: 565-98.
    Google Scholar
  • 30 Roux S, Carteaux JP, Hess P, Falivene L, Clozel JP. Experimental carotid thrombosis in the guinea pig. Thromb Haemost 1994; 71: 252-6.
    PubMedGoogle Scholar
  • 31 Elg M, Gustafsson D, Deinum J. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb Haemost 1997; 78: 1286-92.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Wong AG, Gunn AC, Ku P, Hollenbach SJ, Sinha U. Relative efficacy of active site-blocked factors IXa, Xa in models of rabbit venous and arteriovenous thrombosis. Thromb Haemost 1997; 77: 1143-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Blackburn MN, Feuerstein GZ. Anti-factor IX monoclonal antibody: extended duration of therapeutic protection for arterial thrombosis. Blood 1998; 92 (Suppl. 01) 670 (abstr.)
    PubMedGoogle Scholar
  • 34 Ahmad SS, Rawala-Sheikh R, Walsh PN. Platelet receptor occupancy with factor IXa promotes factor X activation. J Biol Chem 1989; 264: 20012-6.
    PubMedGoogle Scholar
  • 35 Sun Y, Gailani D. Identification of a factor IX binding site on the third apple domain of activated factor XI. J Biol Chem 1996; 271: 29023-8.
    CrossrefPubMedGoogle Scholar
  • 36 Jones ME, Griffith MJ, Monroe DM, Roberts HR, Lentz BR. Comparison of lipid binding and kinetic properties of normal, variant, and γ-carboxyglutamic acid modified human factor IX and factor IXa. Biochemistry 1985; 24: 8064-9.
    CrossrefPubMedGoogle Scholar
  • 37 Larson PJ, Stanfield-Oakley SA, VanDusen WJ, Kasper CK, Smith KJ, Monroe DM, High KA. Structural integrity of the γ-carboxyglutamic acid domain of human blood coagulation factor IXa is required for its binding to cofactor VIIIa. J Biol Chem 1996; 271: 3869-76.
    CrossrefPubMedGoogle Scholar
  • 38 Himber J, Burcklen L, Kelley RF, Kirchhofer D. A soluble tissue factor mutant inhibits thrombus formation in guinea pig carotid arteries. Thromb Haemost 1997; 78: 591-2 (abs.)
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Levine MN, Hirsh J, Salzman EW. Side effects of antithrombotic therapy. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW. eds Philadelphia: J. B. Lippencott; 1994: 936-55.
    Google Scholar
  • 40 Benedict CR, Ryan J, Todd J, Kuwabara K, Tijburg P, Cartwright Jr. J, Stern D. Active site-blocked factor Xa prevents thrombus formation in the coronary vasculature in parallel with inhibition of extravascular coagulation in a canine thrombosis model. Blood 1993; 81: 2059-66.
    PubMedGoogle Scholar
  • 41 Klement P, Liao P, Hirsh J, Johnston M, Weitz J. Hirudin causes more bleeding than heparin in a rabbit ear bleeding model. J Lab Clin Med 1998; 132: 181-5.
    CrossrefPubMedGoogle Scholar
  • 42 Hovig T, Dodds WJ, Rowsell HC, Mustard JF. The transformation of hemostatic platelet plugs in normal and factor IX deficient dogs. Am J Pathol 1968; 53: 355-74.
    PubMedGoogle Scholar
  • 43 Sixma JJ, Van den Berg A. The haemostatic plug in haemophilia A: a morphological study of haemostatic plug formation in bleeding time skin wounds of patients with severe haemophilia. A Brit J Haematol 1984; 58: 741-53.
    PubMedGoogle Scholar
  • 44 Montoney M, Gardell SJ, Marder VJ. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model. Circulation 1995; 91: 1540-4.
    CrossrefPubMedGoogle Scholar
  • 45 Smokovitis A, Astrup T. Patterns of activation and inhibition of fibrinolysis in the normal skin of rat, guinea pig and rabbit. J Investigative Dermatology 1978; 70: 321-5.
    CrossrefPubMedGoogle Scholar